An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
* New prescription or change in dose/schedule of SSRI (citalopram, escitalopram, sertraline, paroxetine), OR
* Concurrent SSRI (citalopram, escitalopram, sertraline, paroxetine) and new prescription/change in SNRI (desvenlafaxine, duloxetine, and venlafaxine) / bupropion.
Depressive symptoms confirmed by PHQ8 assessment (\>5 indicating at least mild depressive symptoms)
UPMC patient (or able/willing to become one) and has UPMC provider (or able/willing to obtain one)
Signed consent to join Pitt+Me Discovery biobanking research study.
English-speaking
You may not be if
Inability to receive CMM at specific pharmacy/pharmacist
Comorbid diagnosis of schizophrenia (patient-reported)
Untreated sleep disorder (patient-reported)
Pitt+Me Discovery participant who has elected to not receive return of results, or who has already received results previously
Clareo Health | An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
